Nanocarriers based therapy and diagnosis of brain diseases: cross the blood-brain barrier
Source abstract
Abstract
The blood-brain barrier (BBB) is the protective interface that isolates the central nervous system from circulating blood, which restricts approximately 98% of small molecule drugs and nearly all large molecules from entering the brain. Current methods to bypass the BBB, such as laser-guided interstitial thermal therapy and magnetic resonance guided focused ultrasound, are fraught with risks like impairing BBB integrity and brain damage, and are not suitable for long-term treatment. Nanocarriers have emerged as promising tools due to their ability to enhance drug delivery across the BBB while minimizing systemic toxicity. These nanocarriers leverage mechanisms including receptor-mediated, carrier-mediated, cell mediated and extra-stimuli mediated transport to improve BBB traverse and brain targeting. The review evaluates these strategies separately, discussing their potential and limitations for clinical application, and highlights recent advancements in integrating and optimizing nanocarriers utilizing synergistic strategies for the treatment and diagnosis of neurological disorders, including tumors, Alzheimer's disease, Parkinson's disease, and brain infections.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Barrier Structure and Function Studies · Nanoparticle-Based Drug Delivery · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Shenzhen Institute for Drug Control
Wuhan Institute of Technology
Chongqing University
Funding
National Natural Science Foundation of China · China Postdoctoral Science Foundation · Shenzhen Science and Technology Program
References (100+)
Show source-provided references
1. 10.1038/s41573-021-00139-y10.1038/s41573-021-00139-y ↗
2. 10.1016/j.cell.2015.10.06710.1016/j.cell.2015.10.067 ↗
3. 10.7150/thno.6968210.7150/thno.69682 ↗
4. 10.1002/adma.20180136210.1002/adma.201801362 ↗
5. 10.1038/s41392-023-01481-w10.1038/s41392-023-01481-w ↗
6. 10.1016/j.addr.2019.11.00910.1016/j.addr.2019.11.009 ↗
7. 10.1002/smll.20230261310.1002/smll.202302613 ↗
8. 10.1016/j.addr.2011.11.00210.1016/j.addr.2011.11.002 ↗
9. 10.2147/IJN.S45085310.2147/IJN.S450853 ↗
10. 10.1016/j.addr.2019.01.00510.1016/j.addr.2019.01.005 ↗
11. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
12. 10.1021/acsnano.3c1067410.1021/acsnano.3c10674 ↗
13. 10.1039/C8CS00805A10.1039/C8CS00805A ↗
14. 10.2967/jnumed.122.26389510.2967/jnumed.122.263895 ↗
15. Application of nanoparticles for cyclic hyperthermia in adjuvant therapy of glioblastoma multiforme (ANCHIALE). Available from: https://clinicaltrials.gov/study/NCT06271421?cond=glioblastoma&intr=nanoparticle&rank=2&tab=table
16. Nu-0129 in treating patients with recurrent glioblastoma or gliosarcoma undergoing surgery. Available from: https://clinicaltrials.gov/study/NCT03020017?cond=glioblastoma&intr=nanoparticle&rank=3
17. A study to evaluate the safety tolerability and immunogenicity of EGFR(V)-EDV-Dox in subjects with recurrent glioblastoma multiforme (GBM) (CerebralEDV). Available from: https://clinicaltrials.gov/study/NCT02766699?cond=glioblastoma&intr=nanoparticle&rank=4&tab=results
18. Mtx110 by convection-enhanced delivery in treating participants with newly-diagnosed diffuse intrinsic pontine glioma (PNOC015). Available from: https://clinicaltrials.gov/study/NCT03566199?cond=brain%20tumor&intr=nanoparticle&rank=6&tab=results
19. Radiosensitization of multiple brain metastases using AGuIX gadolinium based nanoparticles (NANO-RAD). Available from: https://clinicaltrials.gov/study/NCT02820454?cond=brain%20tumor&intr=nanoparticle&rank=4&tab=results
20. 10.1136/bmjopen-2018-02359110.1136/bmjopen-2018-023591 ↗
21. Aguix nanoparticles with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma (NANO-GBM). Available from: https://clinicaltrials.gov/study/NCT04881032?cond=glioblastoma&intr=nanoparticle&rank=1
22. 10.1186/s12885-023-10829-y10.1186/s12885-023-10829-y ↗
23. Radiotherapy of multiple brain metastases using AGuIX® (NANORAD2). Available from: https://clinicaltrials.gov/study/NCT03818386?cond=brain%20tumor&intr=nanoparticle&rank=1&tab=results
24. Evaluating AGuIX® nanoparticles in combination with stereotactic radiation for brain metastases (NANOSTEREO). Available from: https://clinicaltrials.gov/study/NCT04094077?cond=brain%20tumor&intr=nanoparticle&rank=3&tab=results
25. Stereotactic brain-directed radiation with or without Aguix gadolinium-based nanoparticles in brain metastases. Available from: https://clinicaltrials.gov/study/NCT04899908?cond=brain%20tumor&intr=nanoparticle&rank=2
26. Study of APH-1105 in patients with mild to moderate Alzheimer’s disease. Available from: https://clinicaltrials.gov/study/NCT03806478?cond=Alzheimer%27s%20Disease&intr=nanoparticle&rank=1&tab=results
27. 31P-MRS imaging to assess the effects of CNM-Au8 on impaired neuronal redox state in Parkinson’s disease (REPAIR-PD). Available from: https://clinicaltrials.gov/study/NCT03815916?cond=Parkinson%27s%20disease&intr=nanoparticle&rank=1&tab=results
28. Australasian nanoparticle-mediated magnetically enhanced diffusion for ischemic stroke (AusNanoMED). Available from: https://clinicaltrials.gov/study/NCT06495671?cond=Stroke&intr=nanoparticle&rank=1&tab=results
29. Pulse endovascular reperFUSION for acute ischemic stroke (PERFUSION AIS). Available from: https://clinicaltrials.gov/study/NCT06052969?cond=Stroke&intr=nanoparticle&rank=3&tab=table
30. 10.1146/annurev-cellbio-100617-06260810.1146/annurev-cellbio-100617-062608 ↗
31. 10.1152/physrev.00037.201810.1152/physrev.00037.2018 ↗
32. 10.1186/s12987-020-00230-310.1186/s12987-020-00230-3 ↗
33. 10.1038/s41467-022-28785-910.1038/s41467-022-28785-9 ↗
34. 10.1038/s41467-022-29657-y10.1038/s41467-022-29657-y ↗
35. 10.1152/ajpcell.00605.202310.1152/ajpcell.00605.2023 ↗
36. 10.1039/C5BM00383K10.1039/C5BM00383K ↗
37. 10.1016/j.cub.2023.09.02710.1016/j.cub.2023.09.027 ↗
38. 10.1161/CIRCRESAHA.120.31800310.1161/CIRCRESAHA.120.318003 ↗
39. 10.1016/j.conb.2018.12.01410.1016/j.conb.2018.12.014 ↗
40. 10.1161/CIRCRESAHA.119.31646310.1161/CIRCRESAHA.119.316463 ↗
41. 10.15252/embj.202110989010.15252/embj.2021109890 ↗
42. 10.1038/s41574-019-0213-710.1038/s41574-019-0213-7 ↗
43. 10.1016/S1474-4422(23)00377-010.1016/S1474-4422(23)00377-0 ↗
44. 10.1007/s00401-024-02695-010.1007/s00401-024-02695-0 ↗
45. 10.1038/s41423-021-00757-x10.1038/s41423-021-00757-x ↗
46. 10.1038/nature0952210.1038/nature09522 ↗
47. 10.1161/CIRCRESAHA.120.31747310.1161/CIRCRESAHA.120.317473 ↗
48. 10.1016/j.neuron.2022.02.01710.1016/j.neuron.2022.02.017 ↗
49. 10.1172/jci.insight.12567910.1172/jci.insight.125679 ↗
50. 10.1161/STROKEAHA.123.04524810.1161/STROKEAHA.123.045248 ↗
51. 10.1038/s41380-022-01511-z10.1038/s41380-022-01511-z ↗
52. 10.1177/0271678X1880146710.1177/0271678X18801467 ↗
53. 10.1038/s41586-024-07283-610.1038/s41586-024-07283-6 ↗
54. 10.1186/s12987-022-00346-810.1186/s12987-022-00346-8 ↗
55. 10.3390/ijms2102067910.3390/ijms21020679 ↗
56. 10.1111/bpa.1326510.1111/bpa.13265 ↗
57. 10.1016/j.matbio.2018.05.00910.1016/j.matbio.2018.05.009 ↗
58. 10.1136/svn-2018-00019810.1136/svn-2018-000198 ↗
59. 10.3390/ijms24241714610.3390/ijms242417146 ↗
60. 10.1146/annurev-neuro-091922-03120510.1146/annurev-neuro-091922-031205 ↗
61. 10.1038/nrn182410.1038/nrn1824 ↗
62. 10.1016/j.phrs.2024.10730810.1016/j.phrs.2024.107308 ↗
63. 10.1093/neuonc/noaa26610.1093/neuonc/noaa266 ↗
64. 10.1016/j.drup.2015.02.00210.1016/j.drup.2015.02.002 ↗
65. 10.1016/S0140-6736(20)32205-410.1016/S0140-6736(20)32205-4 ↗
66. 10.1016/j.bcp.2023.11552210.1016/j.bcp.2023.115522 ↗
67. 10.1016/j.cell.2023.08.02110.1016/j.cell.2023.08.021 ↗
68. 10.1016/S1474-4422(21)00030-210.1016/S1474-4422(21)00030-2 ↗
69. 10.1016/S1474-4422(21)00330-610.1016/S1474-4422(21)00330-6 ↗
70. 10.1007/s40820-022-00847-z10.1007/s40820-022-00847-z ↗
71. 10.1016/S0140-6736(21)00218-X10.1016/S0140-6736(21)00218-X ↗
72. 10.1128/CMR.00190-1910.1128/CMR.00190-19 ↗
73. 10.1186/s12951-022-01450-510.1186/s12951-022-01450-5 ↗
74. 10.7150/thno.6480610.7150/thno.64806 ↗
75. 10.1016/j.biomaterials.2022.12190410.1016/j.biomaterials.2022.121904 ↗
76. 10.1186/s12951-023-01807-410.1186/s12951-023-01807-4 ↗
77. 10.3390/pharmaceutics1204037110.3390/pharmaceutics12040371 ↗
78. 10.1016/j.apsb.2020.11.02010.1016/j.apsb.2020.11.020 ↗
79. 10.1016/j.addr.2019.04.00810.1016/j.addr.2019.04.008 ↗
80. 10.1016/j.addr.2022.11461910.1016/j.addr.2022.114619 ↗
81. 10.1039/D1NR03553C10.1039/D1NR03553C ↗
82. 10.1016/j.jconrel.2024.02.00410.1016/j.jconrel.2024.02.004 ↗
83. 10.1002/adhm.20210031610.1002/adhm.202100316 ↗
84. 10.1021/acs.nanolett.4c0060410.1021/acs.nanolett.4c00604 ↗
85. 10.1016/j.biomaterials.2024.12262210.1016/j.biomaterials.2024.122622 ↗
86. 10.1016/j.actbio.2023.04.02510.1016/j.actbio.2023.04.025 ↗
87. 10.1021/acsnano.3c0176010.1021/acsnano.3c01760 ↗
88. 10.1021/acsanm.3c0212210.1021/acsanm.3c02122 ↗
89. 10.1016/j.ijpharm.2020.11982110.1016/j.ijpharm.2020.119821 ↗
90. 10.1021/acs.nanolett.2c0019110.1021/acs.nanolett.2c00191 ↗
91. 10.1002/adhm.20210081210.1002/adhm.202100812 ↗
92. 10.1016/j.scitotenv.2020.14479710.1016/j.scitotenv.2020.144797 ↗
93. 10.3389/fphar.2024.134218110.3389/fphar.2024.1342181 ↗
94. 10.1016/j.ijpharm.2018.08.04310.1016/j.ijpharm.2018.08.043 ↗
95. 10.1021/acsnano.1c1003410.1021/acsnano.1c10034 ↗
96. 10.1016/j.jconrel.2023.10.00710.1016/j.jconrel.2023.10.007 ↗
97. 10.1021/acsnano.2c0032010.1021/acsnano.2c00320 ↗
98. 10.1039/D2BM02152H10.1039/D2BM02152H ↗
99. 10.3390/polym1404071210.3390/polym14040712 ↗
100. 10.1021/acsnano.3c1195810.1021/acsnano.3c11958 ↗